A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality

The arrival of comprehensive genome sequencing has accelerated the understanding of genetically aberrant advanced cancers and target identification for possible cancer treatment. Fibroblast growth factor receptor (FGFR) gene alterations are frequent findings in various rare and advanced cancers refr...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Jain Nem Kumar, Tailang Mukul, Thangavel Neelaveni, Makeen Hafiz A., Albratty Mohammed, Najmi Asim, Alhazmi Hassan Ahmad, Zoghebi Khalid, Alagusundaram Muthumanickam, Jain Hemant Kumar, Chandrasekaran Balakumar
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Sciendo 2024-03-01
Saila:	Acta Pharmaceutica
Gaiak:	fgfr tyrosine kinase inhibitors fda approval erdafitinib infigratinib pemigatinib futibatinib
Sarrera elektronikoa:	https://doi.org/10.2478/acph-2024-0005
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!